ClinicalTrials.gg
RecruitingNCT06351475ALBUCHIPUpdated Sep 29, 2026

Efficacy of Intraoperative Use of 20% Albumin Combined With Ringer Lactate Versus Ringer Lactate During Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy

An interventional study of Intra-operative albumin administration and Control in Peritoneal Neoplasms, Hyperthermic Intraperitoneal Chemotherapy and Intraoperative Care, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 8 sites in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Sep 29, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Peritoneal Neoplasms with a site in France — 8 open to participants now, 9 under way, 2 of them phase 3. Peritoneal Neoplasms · France.

Planned enrollment
14th of 32
140 · median 73
Started
2025
with 3 others
No phase
12 of 40
4 open now
Registered
37th of 40
by date
Lead sponsor
2 of 40
Assistance Publique - Hôpitaux de Paris

Among the 40 studies in Peritoneal Neoplasms with a site in France, this one is the 14th largest by planned enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2025, is one of 12 with no phase, and was the 37th registered.

Peritoneal Neoplasms

249 studies on the registry are indexed under Peritoneal Neoplasms; 55 are open to participants now.

Browse Peritoneal Neoplasms studies →

Open to participants now

8 of the 40 studies in Peritoneal Neoplasms with a site in France are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 49 Peritoneal Neoplasms studies recruiting now, 35 (71%) set no upper age limit and 8 (16%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Peritoneal Neoplasms with a site in France, or all of them as a file.
02

Study summary

Introduction Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is considered as the standard of care for the treatment of peritoneal metastases. Cytoreductive surgery with HIPEC is characterized by large intra operative fluid shift secondary to surgical resection, peritoneal inflammation and capillary shifts, requesting high volume of intra operative fluid therapy. Previous studies found a strong association between intra operative hypovolemia or volume overload with post operative outcomes. Albumin as an intravenous fluid has been widely studied in critical ill patients, but evaluation of its efficacy during major surgery on post operative clinical outcomes are lacking. We hypothesize that a reduction of intra operative crystalloid volume infusion by using 20% albumin during CRS with HIPEC could improve patients' prognosis. The aim of this study will be to assess the efficacy of 20% albumin combined with Ringer Lactate versus Ringer Lactate for fluid therapy during CRS with HIPEC on post operative outcome at 28 day.

Methods and analysis The study protocol has been designed and written in accordance with the Prospective randomised, comparative, controlled, prospective, open-label, with parallel group and multicentre clinical trial.

Recruitment, randomisation and allocation Information on the study and screening of patients will be conducted during the consultation of anaesthesia (= selection visit), 2 months at 3 days before the surgery. Information notice and consent form will be delivered. The day before the surgery, anaesthesiologist who will conduct the pre anaesthetic visit will be able to include patients in the study (=inclusion visit). Randomisation will be done at the inclusion visit after information and signature of consent form of voluntary patients. A randomization number will be assigned. The 1:1 randomisation will be centralized via an online interface ensuring secret group assignment, and based on predefined randomisation lists with variable-size permutation blocks, stratified by center. Randomisation will be accomplished using a computer-generated random sequence.

Randomized Open, Blinded endpoint (PROBE) design. This study is a randomised, comparative, controlled, prospective, open-label, with parallel group and multicentre clinical trial.

Intervention

  • 20% Albumin + Ringer Lactate group (intervention group) Per-operative fluid therapy consisting in Ringer Lactate combined with 20% albumin. Patients will receive a bolus of 3 mL/kg on one hour of 20% albumin from anaesthetic induction. Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.
  • Control group Ringer Lactate for intra operative fluid management based on the latest scientific recommendations. As the the study is an open labelled randomized clinical trial, placebo use is not planned.

Outcome measures The primary outcome will be the Comprehensive Complication Index (CCI score) at day 28 after CRS with HIPEC. Secondary outcomes are mortality at day 28, CCI score at day 7, volume of intra operative and post operative (48h) post operative fluid therapy, cumulated incidence of surgical post operative complications, cumulated incidence of medical post operative complications, need for mechanical ventilation, renal replacement therapy between surgery and day 28, SOFA score variation between pre operative period and 48h after surgery, number of days alive out of intensive care unit and out of hospital until day 28

Sample size calculation To ensure a power of 80%, a number of patients 130 (65 patients by group) will be necessary with a reduction of 13.6 (SD 24) points of the CCI score at day 28 in the intervention group. Because of a risk of neoplastic evolution between anaesthetic consultation and randomisation (10% of early cancellation), a total of 146 patients (73 by group) will be included in the study.

Discussion In summary, ALBUCHIP study will be the first randomized clinical trial assessing efficacy of intraoperative use of 20% albumin combined with Ringer Lactate versus Ringer Lactate during CRS with HIPEC. Results yielded from this study will be helpful for vascular filling during CRS with HIPEC but, thanks to ancillary studies, to improve pathophysiological understanding of this surgery.

03

Conditions studied

  • Peritoneal Neoplasms
  • Hyperthermic Intraperitoneal Chemotherapy
  • Intraoperative Care
  • Fluid Therapy
  • Postoperative Complications

Keywords

  • Cytoreductive surgery
  • Hyperthermic intraperitoneal chemotherapy
  • Albumin administration
  • Fluid therapy
  • Post operative prognosis
  • Randomized clinical trial
  • Open label clinical trial
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients aged 18 years old and older
  • Planned cytoreductive surgery with HIPEC for peritoneal carcinomatosis (from gynaecological or digestive origin)
  • Patient volunteer for the study and provided written
  • Patient affiliated to the French Health Insurance

Exclusion criteria

Exclusion Criteria:

  • Adults >75 years old
  • Functional status rendering the patient ineligible for cytoreduction with CHIP ( > 2 or index \< 75)
  • Pre-existing preoperative conditions affecting albuminemia (hepatic cirrhosis, nephrotic syndrome, exudative enteropathy, malnutrition)
  • Severe preoperative hypoalbuminemia (albuminemia \< 20 g/L)
  • History of chronic left heart failure with reduced (left ventricular ejection fraction \< 40%)
  • Patients at high risk of perioperative and postoperative pulmonary complications (atelectasis, significant pleural effusions)
  • Significant ascites with preoperative respiratory repercussions
  • Uncontrolled diabetes ( > 8.5%)
  • Allergy to exogenous human albumin and its .
  • to the administration of Ringer's lactate (history of allergy)
  • Hyperkalemia > 6.0 mmol/L
  • Hypercalcemia (total calcium > 2.60 mmol/L)
  • Chronic use of digitalis and hyperkalemic diuretics
  • Pregnancy, breastfeeding
  • Known preoperative renal failure ( \< 30 mL/min/1.73m2 or extrarenal purification)
  • Recent brain trauma \< 6 months (traumatic, ischemic, or hemorrhagic)
  • Participation in another interventional study involving human subjects or being in the exclusion period following a previous study involving human subjects, if applicable
  • Patient deprived of liberty
  • Patient under guardianship or curatorship
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    20% Albumin + Ringer Lactate group

    Per-operative fluid therapy consisting in Ringer Lactate combined with 20% albumin. Patients will receive a bolus of 3 mL/kg on one hour of 20% albumin from anaesthetic induction. Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.

    Other: Intra-operative albumin administration

  • Active comparator
    Control group

    Ringer Lactate for intra operative fluid management based on the latest scientific recommendations. As the the study is an open labelled randomized clinical trial, placebo use is not planned.

    Other: Control

Interventions

  • OtherIntra-operative albumin administration

    Patients randomized in the intervention group (20% albumin + Ringer Lactate) will receive, during cytoreductive surgery with HIPEC, fluid therapy consisting in Ringer Lactate (based on a fluid management protocol specifically set up for the study, and based on latest recommendations) combined with 20% albumin. Patients randomized in the intervention group will receive a bolus of 3 mL/kg on one hour of 20% albumin from anesthetic induction . Dosage of albuminemia will be done 2 hours after the end of the bolus (target of 35-45 g/L of intra operative albuminemia). Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.

  • OtherControl

    Ringer lactate

06

What researchers measure

Primary outcomes

  1. Comprehensive Complication Index score

    The Comprehensive Complication Index (CCI) is a score ranging from 0 to 100, calculated using all complications and their treatment after abdominal surgery. The CCI is that it is a linear scale ranging from 0 to 100, where 100 represents death

    Time frame: At day 28

Secondary outcomes

  1. Comprehensive Complication Index score

    The Comprehensive Complication Index (CCI) is a score ranging from 0 to 100, calculated using all complications and their treatment after abdominal surgery. The CCI is that it is a linear scale ranging from 0 to 100, where 100 represents death

    Time frame: At day 7

  2. Volume of intra operative and post operative fluid therapy

    Time frame: 48 hours after surgery

  3. Cumulative incidence of surgical post operative complications

    Time frame: Up to day 28

  4. Incidence of infectious complications

    Time frame: Up to day 28

  5. Number of days under mechanical ventilation outside the operating room

    Between surgery and day 28

    Time frame: Up to day 28

  6. Number of days under renal replacement therapy

    Between surgery and day 28

    Time frame: Up to day 28

  7. Sequential organ failure assessment (SOFA) score variation

    Between pre operative period and 48h after surgery

    Time frame: 48 hours after surgery

  8. Number of days alive out of intensive care unit

    Time frame: Up to day 28

  9. Number of days alive out of hospital

    Time frame: Up to day 28

  10. Incidence of medical complications

    Time frame: Up to day 28

  11. Cumulative incidence of death in intensive care unit

    Time frame: Up to day 28

  12. Cumulative incidence of death in hospital

    Time frame: Up to day 28

  13. SOFA score

    Sequential Organ Failure Assessment Score varies from 0 to 4 and permit to assess organ failure. A higher score indicates better neurological function

    Time frame: At day 28

  14. Number of days under vasopressors

    Time frame: Up to day 28

  15. Proportion of patients with allergic complications to albumin

    Time frame: At day 133

07

Study locations

8 of 8 sites recruiting
08

References and documents

Publications

  • Deniau B, Moreau A, Monsel A, Faitot V, Pottecher J, Zoric L, Suria S, Bankole E, Michelet D, Poirier N, Plaud B, Chaix C, Biard L, Depret F. Efficacy of intraoperative use of 20% albumin in combination with Ringer's lactate versus Ringer's lactate during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: protocol for a randomised controlled, open-label clinical trial (ALBUCHIP trial). BMJ Open. 2026 Apr 27;16(4):e109391. doi: 10.1136/bmjopen-2025-109391. PubMed 42044958 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Oct 2027, 25 months after the start.

Of 34 interventional studies with no phase under Peritoneal Neoplasms, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 80. This study's planned 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2024
First posted
Apr 8, 2024
StartActual
Sep 3, 2025
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Hôpital Lyon Sud Pierre Bénite · Lyon, France
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    1 site added
    Show site
    • Hôpital Lyon Sud Pierre Bénite · Lyon, France

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06351475
Responsible party
Sponsor
First posted
Apr 8, 2024
Start date
Sep 3, 2025
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Arthur Moreau, Dr
Contact
arthur.moreau@aphp.fr
142499394 ext. +33
Jérôme Lambert, Pr
Contact
jerome.lambert@u-paris.fr
142499742 ext. +33

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion